Assertio Holdings Earnings Call Transcripts
Fiscal Year 2025
-
Q4 2025 sales declined due to ROLVEDON inventory timing, but full-year sales grew to $117.1M, led by ROLVEDON. 2026 guidance projects $110M–$125M revenue and $28M–$40M adjusted EBITDA, with ROLVEDON as the primary growth driver and legacy assets expected to decline.
-
Strong Q3 results driven by a Rosedown sales pull forward led to higher revenue and EBITDA, with guidance narrowed for 2025. Rosedown and Synthesan showed growth, while Indocin faced generic pressure. Cash flow will temporarily dip due to sales timing.
-
Q2 2025 saw $28.8M in sales, strong ROLVEDON and SYMPAZAN growth, and improved adjusted EBITDA. Legal settlements, Otrexup exit, and cost actions sharpened focus on core assets, with guidance narrowed and profitability outlook raised.
-
A transformation-focused specialty pharma is prioritizing growth assets Rolvedon and Sympazan, reducing legal exposure, and pursuing M&A to drive future expansion. Financial guidance is maintained, with Rolvedon expected to expand market share and new strategic deals anticipated.
-
Q1 2025 sales were $26M, with gross margin at 70% and adjusted EBITDA at $0.2M. Legal liabilities were largely divested, and guidance for 2025 remains unchanged, with growth expected from ROLVEDON and Sympazan as payer coverage expands.
Fiscal Year 2024
-
2024 was a stabilization year, highlighted by strong Rolvedon sales, Indocin erosion from generics, and portfolio optimization. 2025 guidance reflects modest growth, ongoing legal and market uncertainties, and a focus on transformation and strategic opportunities.
-
Q3 sales declined slightly to $28.7M, with Rolvedon stable at $15M and Indocin down due to generics. Gross margin improved to 74%, net loss narrowed, and cash remained strong. Guidance is unchanged as the company focuses on Rolvedon growth and new asset acquisitions.
-
Leadership is focused on optimizing a small portfolio, with Rolvedon as the main growth driver. Expansion into hospital and 340B markets, plus a completed same-day dosing study, support long-term growth. Cash reserves enable potential acquisitions and creative deal structuring.
-
Q2 2024 saw ROLVEDON drive sequential growth amid Indocin's expected decline, with total sales at $30.7M and adjusted EBITDA at $5M. Cash reserves rose to $88.4M, and 2024 guidance was maintained. ROLVEDON is expected to remain the primary growth driver.
-
Strong Q1 results and a robust cash position support guidance for $110–$125 million in 2024 sales and $20–$30 million in adjusted EBITDA. Rolvedon leads growth, with potential to reach $100 million in sales, while a same-day dosing trial could provide further upside.